Kamada Ltd. (KMDA) EPS Estimated At $0.07

July 13, 2018 - By whatsonthorold

Analysts expect Kamada Ltd. (NASDAQ:KMDA) to report $0.07 EPS on August, 7.They anticipate $0.06 EPS change or 46.15 % from last quarter’s $0.13 EPS. KMDA’s profit would be $2.81 million giving it 19.46 P/E if the $0.07 EPS is correct. After having $0.03 EPS previously, Kamada Ltd.’s analysts see 133.33 % EPS growth. The stock increased 1.87% or $0.1 during the last trading session, reaching $5.45. About 41,505 shares traded or 137.16% up from the average. Kamada Ltd. (NASDAQ:KMDA) has declined 30.28% since July 13, 2017 and is downtrending. It has underperformed by 42.85% the S&P500.

Kamada Ltd. (NASDAQ:KMDA) Ratings Coverage

Among 2 analysts covering Kamada (NASDAQ:KMDA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Kamada had 2 analyst reports since February 2, 2018 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, February 8 report.

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. The company has market cap of $218.70 million. It operates through two divisions, Proprietary Products and Distribution. It has a 17.81 P/E ratio. The company??s respiratory products include Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency ; Bramitob to manage chronic pulmonary infection; and FOSTER for the treatment of asthma.

More recent Kamada Ltd. (NASDAQ:KMDA) news were published by: Nasdaq.com which released: “Kamada Receives Positive Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for …” on July 10, 2018. Also Investorplace.com published the news titled: “4 Undervalued MedTech Stocks to Consider Amid Volatility” on June 19, 2018. Streetinsider.com‘s news article titled: “Kamada (KMDA) Reports Positive Scientific Advice from European Medicines Agency on New Phase 3 Study Design …” with publication date: July 11, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.